P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Targeting the Phosphatidylinositol 3-Kinase Pathway in Multiple Myeloma
Hashem Younes,Xavier Leleu,Evdoxia Hatjiharissi,Anne-Sophie Moreau,Teru Hideshima,Paul G. Richardson,Kenneth C. Anderson,Irene M. Ghobrial +7 more
TL;DR: The role of the phosphatidylinositol 3-kinase/Akt pathways in the pathogenesis of multiple myeloma and the potential therapeutic implications of targeting this pathway in the treatment of multipleMyeloma are reviewed.
Journal ArticleDOI
Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma.
Christine Chen,Donna E. Reece,David S. Siegel,Ruben Niesvizky,Ralph V. Boccia,Edward A. Stadtmauer,Rafat Abonour,Paul G. Richardson,Jeffrey Matous,Shaji Kumar,Nizar J. Bahlis,Melissa Alsina,Robert Vescio,Steven Coutre,Dennis Pietronigro,Robert Knight,Jerome B. Zeldis,Vincent Rajkumar +17 more
TL;DR: Safety data confirmed known AEs of lenalidomide plus dexamethasone therapy in patients with relapsed/refractory MM and the most common adverse events were haematological, gastrointestinal, and fatigue.
Journal ArticleDOI
Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines.
Teru Hideshima,Toshiaki Hayashi,Dharminder Chauhan,Masaharu Akiyama,Paul G. Richardson,Kenneth C. Anderson +5 more
TL;DR: It is demonstrated for the first time that inhibiting JNK activity induces growth arrest and activates NF-κB in MM cells.
Journal ArticleDOI
Lenalidomide, Bortezomib, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma: Encouraging Efficacy in High Risk Groups with Updated Results of a Phase I/II Study
Paul G. Richardson,Sagar Lonial,Andrzej Jakubowiak,Sundar Jagannath,Noopur Raje,David Avigan,Irene M. Ghobrial,Robert L. Schlossman,Amitabha Mazumder,Nikhil C. Munshi,David H. Vesole,Robin Joyce,Deborah Doss,Diane Warren,Stephen Hayes,Sarah Kaster,Carol Delaney,Marisa Lauria,Constantine S. Mitsiades,Teru Hideshima,Robert Knight,Dixie-Lee Esseltine,Kenneth C. Anderson +22 more
TL;DR: The aims of this phase l/ll study were to determine the maximum tolerated dose of Len/Bz/Dex (RVD) and to assess safety and efficacy in previously untreated MM pts and to proceed to autologous stem cell transplant (ASCT) after ≥4 cycles.
Journal ArticleDOI
Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications
Teru Hideshima,Dharminder Chauhan,Tanyel Kiziltepe,Hiroshi Ikeda,Yutaka Okawa,Klaus Podar,Noopur Raje,Alexei Protopopov,Nikhil C. Munshi,Paul G. Richardson,Ruben D. Carrasco,Kenneth C. Anderson +11 more
TL;DR: The biologic sequelae of the inhibition of IKKalpha versus IKKbeta in MM cell lines are examined and Combination therapy targeting these kinases therefore represents a promising treatment strategy in MM.